<?xml version='1.0' encoding='utf-8'?>
<document id="9002471"><sentence text="Protein-binding high-performance frontal analysis of (R)- and (S)-warfarin on HSA with and without phenylbutazone."><entity charOffset="99-113" id="DDI-PubMed.9002471.s1.e0" text="phenylbutazone" /></sentence><sentence text="Applicability of high-performance frontal analysis (HPFA) to the stereoselective study of drug-drug interaction upon plasma protein binding has been investigated" /><sentence text=" Racemic warfarin and phenylbutazone were used as model drugs"><entity charOffset="22-36" id="DDI-PubMed.9002471.s3.e0" text="phenylbutazone" /></sentence><sentence text=" An on-line HPFA/HPLC system consisting of a HPFA column (diol-silica column), an extraction column, and a chiral separation column was developed, and human serum albumin solution containing racemic warfarin and/or phenylbutazone was injected directly to the HPFA column"><entity charOffset="215-229" id="DDI-PubMed.9002471.s4.e0" text="phenylbutazone" /></sentence><sentence text=" When the injection volume was large enough, the binding equilibrium in the sample solution was reproduced in the column, and consequently a plateau region appeared on the chromatogram" /><sentence text=" This plateau region contains unbound drug(s)" /><sentence text=" A given volume of eluent in the plateau part was transferred into the extraction column by column-switching" /><sentence text=" The concentrated drug(s) was then transferred to the chiral separation column to determine the unbound concentrations of the enantiomers and/or the competitor" /><sentence text=" The results agreed with those obtained by a conventional ultrafiltration-HPLC method" /><sentence text=" The influence of phenylbutazone upon the protein binding of warfarin is enantioselective"><entity charOffset="18-32" id="DDI-PubMed.9002471.s10.e0" text="phenylbutazone" /></sentence><sentence text=" In warfarin and human serum albumin mixed solution, the unbound concentration of (R)-warfarin was 1"><entity charOffset="82-94" id="DDI-PubMed.9002471.s11.e0" text="(R)-warfarin" /></sentence><sentence text="22 times higher than that of the S-isomer" /><sentence text=" By addition of phenylbutazone, the unbound concentration of (S)-warfarin increased more than that of (R)-warfarin, resulting in the reversed enantioselectivity, i"><entity charOffset="16-30" id="DDI-PubMed.9002471.s13.e0" text="phenylbutazone" /><entity charOffset="102-114" id="DDI-PubMed.9002471.s13.e1" text="(R)-warfarin" /><pair ddi="false" e1="DDI-PubMed.9002471.s13.e0" e2="DDI-PubMed.9002471.s13.e0" /><pair ddi="false" e1="DDI-PubMed.9002471.s13.e0" e2="DDI-PubMed.9002471.s13.e1" /></sentence><sentence text="e" /><sentence text=", the unbound concentration of (S)-warfarin became 1"><entity charOffset="31-43" id="DDI-PubMed.9002471.s15.e0" text="(S)-warfarin" /></sentence><sentence text="19 times larger than that of (R)-warfarin"><entity charOffset="29-41" id="DDI-PubMed.9002471.s16.e0" text="(R)-warfarin" /></sentence><sentence text=" The present method was also applicable to human plasma samples" /><sentence text="" /></document>